Lymphatic dysfunction causes tissue fibrosis, leading to numerous diseases including infertility, heart failure, and pulmonary fibrosis. LYMPHOGENIX Ltd. has identified cell populations and their secreted factors that powerfully promote lymphatic regeneration and possesses foundational technology for their large-scale production. Using these secreted factors, the company is currently developing novel therapeutic approaches to improve endometrial fibrosis at embryo implantation sites. This is expected to improve implantation rates and enhance pregnancy possibilities for those struggling with infertility. Infertility is a serious challenge not only in humans but also in the livestock industry. Through the development of infertility treatment products targeting both humans and livestock, the company aims to improve quality of life through enhanced reproductive function and reduce socioeconomic losses.